uniQure N.V, a Dutch gene therapy company, has named Scott McMillan as its chief operating officer, Sander van Deventer as chief scientific officer, and Christian Klemt as chief accounting officer. The company also announced nominations to its board of directors. McMillan will be responsible for all current good manufacturing process (cGMP) activities at uniQure and all product development functions. He will be based in the company’s Lexington, Mass. facility, and will report to CEO Matt Kapusta.
Van Deventer, a co-founder of uniQure and a board member, will succeed Harald Petry, effective immediately, and report directly to Kapusta. Van Deventer will also resign from the board of directors on the appointment by the shareholders of his replacement, which is expected to occur on Sept. 14.